INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sempra - SRE

Impact · against what's priced in

Sempra (SRE) faces negative pressure from a combined revenue miss, lowered 2025 earnings guidance, and a new securities fraud investigation. Commvault (CVLT) and Entrada Therapeutics (TRDA) are also under legal scrutiny, though the primary focus of the news event is the financial deterioration at Sempra.

SRE−0.70

No priced-in read yet